News
Kenvue, Tylenol
Digest more
“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...
The stock's fall snapped a four-day winning streak.
The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company ...
4h
Barchart on MSNKenvue's Q2 2025 Earnings: What to ExpectSkillman, New Jersey-based Kenvue Inc. (KVUE) operates as a global consumer health company. Valued at $41.9 billion by market ...
Explore more
Results that may be inaccessible to you are currently showing.
Hide inaccessible results